INTRODUCTION
Multipotent stromal cells (MSCs), originally detected in bone marrow, are nonhematopoietic progenitor cells that are defined by their ability to adhere to plastic surfaces and their capacity to differentiate toward different mesodermic lineages, including adipocytes, osteocytes, and chondrocytes [1] . An important characteristic of MSCs is their immunomodulatory capacity. MSCs interfere with differentiation and functions of multiple immunomodulatory cells. In vitro, MSCs suppress the proliferation of T cells upon allogeneic and mitogenic stimulation [2, 3] , they inhibit monocyte-derived dendritic cell differentiation and maturation [4, 5] and the proliferation of B cells and natural killer cells [6, 7] , and they promote the generation of regulatory T cells [8 -10] . Multiple factors have been implicated in the immunomodulatory effects of MSCs, including indoleamine 2,3-dioxygenase (IDO), interleukin-6 (IL-6), prostaglandin E2 (PGE2), and transforming growth factor-␤1 (TGF-␤1) [9, [11] [12] [13] [14] .
The potential therapeutic application of MSCs for immunomodulation has been the subject of many studies over the years. In experimental models, administration of MSCs resulted in prolonged skin graft survival in baboons [15] and in prevention of both graft-versus-host disease (GvHD) [16] and the development of experimental autoimmune encephalomyelitis in mice [17] . The use of MSCs as a cellular therapy is currently explored in clinical trials, aiming at the promotion of engraftment following hematopoietic stem cell transplantation [18] and treatment of GvHD [19] and Crohn's disease [20] .
Expanded bone marrow-derived MSCs have been most widely used for clinical applications, but alternative sources or subpopulations are currently under investigation [21, 22] . The frequency of MSCs in bone marrow is low (0.001%-0.01% of the total mononuclear cell fraction [23] ), and aspirating bone marrow is an invasive procedure. Adipose tissue is an interesting alternative to bone marrow, since it contains an approximately 500-fold higher frequency of MSCs [24, 25] and tissue collection is simple. Moreover, 400,000 liposuctions a year are performed in the U.S. alone, where the aspirated adipose tissue is regarded as waste [26] and could be collected without any additional burden or risk for the donor. Adipose tissue-derived MSCs (AT-MSCs) are already applied in clinical trials [21, 22] , but a systematic comparative study of bone marrow-derived MSCs (BM-MSCs) and AT-MSCs has not been performed. Studies that compared MSCs derived from different sources focused on phenotype, transcription profiling, and differentiation potential [27] [28] [29] [30] [31] [32] [33] . A few studies compared the immunomodulatory properties [30, 32, 34 -36] and showed qualitative similarities between AT-MSCs and BM-MSCs. Quantitative analysis could not be performed in these studies, since different patient groups and different age groups were analyzed. Age is an important variable, since the composition of the MSC population and the functional properties of MSCs change with aging [37, 38] .
In this study we systematically compared the in vitro immunomodulatory capacities of BM-MSCs and AT-MSCs derived from age-matched donors to further define the advantages and disadvantages related to the use of the different tissue sources for MSC therapy. We show that both AT-MSCs and BM-MSCs are able to suppress proliferation of stimulated peripheral blood mononuclear cells (PBMCs) and to inhibit differentiation of monocyte-derived immature dendritic cells (iDCs). However, AT-MSCs show more potent immunomodulatory effects, a difference that is related to higher levels of cytokine secretion.
MATERIALS AND METHODS

Patients
Adipose tissue was dissected as medical waste from nine cadaveric pancreata that were donated for islet transplantation in our center, according to the institutional guidelines regarding the use of waste material. Bone marrow from a group of nine agematched donors was obtained from the iliac crests of healthy donors and from orthopedic patients after written informed consent was obtained, according to procedures that were approved by the medical ethical committee. The mean age of bone marrow donors was 49.2 Ϯ 13.2 years, and the mean age of adipose tissue donors was 54.2 Ϯ 16.0 years ( Table 1) .
Generation of MSCs From Bone Marrow and Adipose Tissue
Bone marrow-derived mononuclear cells were isolated using a Ficoll-Paque density gradient (1.077 g/cm 3 ) and plated at 1.3 ϫ 10 5 /cm 2 in proliferation medium (Dulbecco's modified Eagle's medium-low glucose [DMEM-LG]; Invitrogen, Paisley, U.K., http://www.invitrogen.com) supplemented with 10% fetal calf serum (FCS) (Greiner Bio-One, Alphen a/d Rijn, The Netherlands, http://www.gbo.com/en) and penicillin/streptomycin (P/S) (Invitrogen). Adipose tissue was mechanically disrupted and subsequently digested using collagenase (2 mg/ml; Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands, http://www. sigmaaldrich.com) in proliferation medium. After digestion, the cell suspension was centrifuged to separate the adipocytes from the stromal vascular fraction (SVF). The SVF was filtered, and the cells were plated in culture flasks in culture medium at a density of 1.4 ϫ 10 4 /cm 2 . Cultures were incubated at 37°C and 5% CO 2 . After 3-4 days nonadherent cells were removed, and medium was refreshed every 3-4 days until confluence was reached. The MSC monolayer was detached using trypsin/EDTA (Invitrogen), and cells were reseeded at 4,000 cells per cm 2 for further expansion. The MSCs were characterized by immune phenotyping and used in further experiments at passages 2-5.
Isolation of Human Peripheral Blood Mononuclear Cells and Monocytes
Human PBMCs were isolated from buffy coats obtained from healthy donors from Sanquin Blood Supply (Leiden, The Netherlands, http://www.sanquin.nl/en/) using a Ficoll-Paque density gradient. Monocytes were purified from the freshly prepared mononuclear cell fraction by magnetic activated cell sorting (MACS) using CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany, http://www.miltenyibiotec.com). Cells were separated with a MACS LS column according to the manufacturer's recommendations. 1B Fig. 2 Fig. 3A Fig. 3B Fig. 3C Fig. 4A Fig. 4B Fig. 4C Fig. 4D Fig. 5A Fig. 5B Fig. 5C BM Ϫ7 M dexamethasone, and 50 g/ml vitamin C (both from Sigma-Aldrich). After the first week, 5 mM ␤-glycerophosphate (SigmaAldrich) was added. For adipogenic differentiation, MSCs were incubated with medium consisting of ␣-MEM supplemented with L-glutamine, P/S and 10% FCS, 10 Ϫ7 M dexamethasone, insulin (10 g/ml), indomethacin (5 M), and 3-isobutyl-1-methylxanthine (5 M) (all from Sigma-Aldrich).
After 3 weeks of culture, cells from all differentiation cultures were stained for alkaline phosphatase activity with Fast Blue (Sigma-Aldrich), and calcium deposition was determined with alizarin red (MP Biomedicals LLC, Illkirch Cedex, France, http://www.mpbio.com) staining. Formation of lipid droplets was visualized using Oil Red O staining (Sigma-Aldrich).
Suppression of PBMC Proliferation
The immunosuppressive capacity of MSCs was tested in a coculture of MSCs and PBMCs. MSCs were plated in graded doses in a 96-well flat-bottomed plate in DMEM-LG (Invitrogen) supplemented with 10% FCS (Greiner Bio-One) and P/S (Invitrogen). 
Inhibition of Monocyte-Derived Immature Dendritic Cell Differentiation
iDCs were generated from freshly isolated CD14 ϩ monocytes by culturing 1.0 ϫ 10 6 cells in six-well plates in RPMI (Invitrogen) containing P/S, L-glutamine, and 10% FCS supplemented with the growth factors IL-4 (10 ng/ml; Invitrogen) and granulocyte macrophage colony-stimulating factor (5 ng/ml; Novartis International, Basel, Switzerland, http://www.novartis.com) for 6 days. To examine the effect of MSCs on monocyte differentiation, irradiated (60 Gy) BM-MSCs and AT-MSCs were added to the culture at an MSC:monocyte ratio of 1:5 to 1:50. All experiments were performed in duplicate. The experiments were performed in direct coculture and in a Transwell coculture system (pore size, 0.4 M; Corning Inc., Lowell, MA, http://www.corning.com). In the Transwell experiments, MSCs were plated in the lower well, and monocytes were added in the Transwell insert. At day 6 the iDCs were harvested from the coculture and analyzed for expression of CD1a and CD14 by flow cytometry.
Flow Cytometry
After trypsinization, MSC cultures were analyzed for expression of surface markers using CD90-FITC, CD73-PE, CD45-FITC, CD34-PE, HLA-DR-PE, HLA-ABC-FITC, CD80-PE (BD Biosciences, San Diego, CA, http://www.bdbiosciences.com), and CD105-FITC (Ancell, Bayport, MN, http://www.ancell.com). The monocytes from the coculture experiments were collected at day 6 and analyzed for surface marker expression using CD1a-FITC and CD14-PE (BD Biosciences). Cells were incubated with fluorescent-labeled antibodies 30 minutes at 4°C in the dark. After being washed with phosphate-buffered saline/1% albumin they were analyzed using a FACSCanto II (BD Biosciences). The analysis of the acquired data was done with FlowJo software version 7.6.1 (Tree Star, Ashland, OR, http://www.treestar.com).
Cytokine Assay
To determine cytokine concentrations in the supernatants of PBMC proliferation cultures and the monocyte cultures, cell-free supernatant was collected at days 5 and 6, respectively, and stored at Ϫ20°C until use. Cytokine concentrations were measured using the Bio-Plex Pro Human Cytokine Th1/Th2 panel (Bio-Rad, Hercules, CA, http://www.bio-rad.com). To analyze constitutive cytokine secretion, BM-MSCs and AT-MSCs were plated at confluent cell concentrations (2.0 ϫ 10 5 cells in a 12-well plate) and cultured without medium replacement. At day 7, cell-free culture supernatant was collected and stored at Ϫ20°C, and MSCs were harvested and counted. Cytokine concentrations were measured using the Bio-Plex Pro Human Cytokine 27-plex panel (Bio-Rad) or sandwich enzyme-linked immunosorbent assay (BD Biosciences).
MTT Assay
In a 96-well plate, 2.0 ϫ 10 4 MSCs were plated in DMEM-LG (Invitrogen) supplemented with 10% FCS (Greiner Bio-One) and P/S (Invitrogen). After overnight adherence, the medium was replaced with 100 l of colorless Iscove's modified Dulbecco's medium (Invitrogen) supplemented with P/S and 10% FCS. For measurement of the metabolic activity 10 l of 12 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) stock solution (Life Technologies, Grand Island, NY, http://www. lifetech.com) was added to each well and incubated for 4 hours at 37°C. Then 75 l of the medium was removed and 100 l of DMSO was added and incubated for 10 minutes at 37°C. Absorbance was read at 540 nm.
Interferon-␥ Stimulation of MSCs
To analyze IDO upregulation induced by interferon-␥ (IFN-␥), MSCs were plated at a concentration of 2.0 ϫ 10 5 cells per well in a 12-well plate, and IFN-␥ was added to the culture medium (500 U/ml; Sigma-Aldrich). At time points of 0, 4, 8, and 24 hours, RNA was extracted, and cell-free supernatant was collected and stored for further analysis at Ϫ20°C.
Gene Expression Analysis
RNA was extracted from MSCs using the RNeasy micro kit from Qiagen (Hilden, Germany, http://www.qiagen.com). cDNA was synthesized with Superscript III RT (Invitrogen). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analyses were performed on a StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, http://www. appliedbiosystems.com) using SYBR Green reagent (Roche Diagnostics, Almere, The Netherlands, http://www.roche-appliedscience.com). The following primer sets were used: IDO: forward, 5Ј-CCTGAGGAGCTACCATCTGC-3Ј, and reverse, 5Ј-TCAGTGCCTCCAGTTCCTTT-3Ј; IL-6: forward, 5Ј-TTCAATGAG-GAGACTTGCCTG-3Ј, and reverse, 5Ј-ACAACAACAATCTGAGGT-GCC-3Ј; and ␤-actin: forward, 5Ј-AGGCATCCTCACCCTGAAGTA-3Ј, and reverse, 5Ј-CACACGCAGCTCATTGTAGA-3Ј. All RT-qPCR data were normalized to ␤-actin expression, and the data were analyzed using the ␦-Ct method.
RESULTS
BM-MSCs and AT-MSCs Have Similar Phenotype and Differentiation Capacity
Immunophenotypic analysis of BM-MSCs and AT-MSCs showed a similar surface marker expression profile (Fig. 1A-1C ). This profile is in accordance with the phenotypical definition of MSCs by the International Society for Cellular Therapy [1] , with the exception of CD34, which was expressed only on a fraction of AT-MSCs (27.4% Ϯ 9.8%, n ϭ 4) (Fig. 1C) .
Both BM-MSCs and AT-MSCs were able to differentiate toward the osteogenic and adipogenic lineages (Fig. 2) . No differentiation was observed for MSCs that were cultured in medium only.
AT-MSCs Are More Potent in Their Suppression of PBMC Proliferation Than BM-MSCs
Functional Suppression
Both BM-MSCs and AT-MSCs were able to suppress the proliferation of PBMCs in a dose-dependent fashion (Fig. 3A) . However, addition of equal numbers of AT-MSCs resulted in significantly higher levels of suppression of PBMC proliferation compared with BM-MSCs (Fig. 3A) . Approximately three times as many BMMSCs were needed to obtain the suppressive effect that was observed with AT-MSCs. At an MSC:PBMC ratio of 1:3, both BMMSCs and AT-MSCs showed almost complete inhibition of PBMC proliferation. Control experiments, replacing MSCs with K562 
Cytokine Production
In the presence of increasing amounts of both BM-MSCs and AT-MSCs, the concentrations of the proinflammatory cytokines IL-12, tumor necrosis factor-␣ (TNF-␣), and IFN-␥ in the culture supernatants of PBMC-MSC coculture decreased in a dose-dependent fashion (Fig. 3B) . At an MSC:PBMC ratio of 1:30, the IFN-␥ concentrations in the culture supernatant were significantly lower (p Ͻ .01) in the presence of AT-MSCs compared with BM-MSCs (Fig. 3B) .
The upregulation of IDO expression in MSCs following IFN-␥ stimulation is regarded as an important mechanism for the MSCinduced suppression of PBMC proliferation. Therefore, we investigated the level and speed of induction of IDO expression in response to IFN-␥ stimulation in BM-MSCs and AT-MSCs. Following IFN-␥ stimulation, expression of IDO mRNA was induced in both BM-MSC and AT-MSC populations. Between 4 and 24 hours after IFN-␥ stimulation, the average IDO expression in AT-MSCs was higher than in BM-MSCs. However, because of the high variation, the difference did not reach statistical significance. At 8 hours, the highest expression levels of IDO were observed for both AT-MSCs and BM-MSCs (Fig. 3C) .
AT-MSCs Are More Potent in Inhibiting Dendritic Cell Formation Than BM-MSCs
BM-MSCs and AT-MSCs were further tested for their capacity to inhibit the differentiation of CD1a Ϫ CD14 ϩ monocytes toward CD1a ϩ CD14 Ϫ iDCs. Both AT-MSCs and BM-MSCs exhibited this inhibitory effect at an MSC:monocyte ratio of 1:10 ( Fig. 4A, 4B) . Also in this immunomodulation assay, a clear difference in the dose-response relation was observed, in favor of AT-MSCs ( Addition of BM-MSCs and AT-MSCs increased the concentrations of the anti-inflammatory cytokine IL-10 in supernatants of cultures from monocytes that were differentiated toward iDCs (Fig. 4D) . Again, addition of AT-MSCs resulted in a significantly higher concentrations of IL-10 than addition of BM-MSCs (1,481.0 Ϯ 118.8 pg/ml vs. 961.8 Ϯ 159.5 pg/ml, n ϭ 3, p Ͻ .01).
AT-MSCs Secrete Higher Concentrations of Cytokines Compared With BM-MSCs
To investigate whether the difference in potency in the various immunomodulatory assays could be explained by a generally increased cytokine secretion by AT-MSCs compared with BMMSCs, cytokine profiling was performed in culture supernatant of unstimulated MSCs. After 7 days of culture, no differences were observed in the number of cells between AT-MSC and BM-MSC cultures. Culture supernatants from AT-MSC cultures generally contained higher concentrations of cytokines than culture supernatants from BM-MSCs, and the reverse phenomenon was never observed. The differences were significant for the cytokines IL-6, IL-8, IL-12, Eotaxin, and TGF-␤1 (Fig. 5A) . The largest differences were found for IL-6 and TGF-␤1. For IL-6, this difference in cytokine concentrations was confirmed at the transcriptional level (Fig. 5B) .
We hypothesized that the generally enhanced levels of multiple cytokines in AT-MSCs are the result of a higher metabolic activity in AT-MSCs. To test this hypothesis, we directly analyzed the metabolic activity of BM-MSCs and AT-MSCs using an MTT assay. Indeed, the AT-MSCs showed a higher average metabolic activity compared with BM-MSCs; however, this observation reached only borderline significance (p ϭ .06) (Fig. 5C ). 
DISCUSSION
AT-MSCs have been considered as an alternative to BM-MSCs for clinical application [16, 30, 39] . In this study we performed an in vitro systematic comparison of BM-MSCs and AT-MSCs from agematched donors. We found a similar phenotype and capacity for multilineage in vitro differentiation toward the osteogenic and adipogenic lineages. We observed that both BM-MSCs and ATMSCs exhibited the capacity to inhibit PBMC proliferation as well as monocyte differentiation toward iDCs. However, the doseresponse curve for AT-MSCs was clearly different from that for BM-MSCs. To acquire the same level of suppression, fewer ATMSCs were required than BM-MSCs. Furthermore, AT-MSCs secreted higher levels of cytokines than BM-MSCs, which corresponded to a higher metabolic activity.
The expression of surface marker CD34 on a subpopulation of the AT-MSCs has been described previously. This expression decreases during culture expansion [40 -42] , explaining the observed variation. The relevance of CD34 expression on AT-MSCs is currently unclear. CD34
ϩ /CD31 Ϫ cells have been detected at perivascular locations in adipose tissue [43] . These cells can differentiate in vitro toward endothelial cells [44] , which suggests that they might play role in vasculogenesis. Such a preferred role for these CD34 ϩ /CD31 Ϫ cells is not supported by the findings of Suga et al., who showed similar capabilities for capillary-network formation for CD34 ϩ and CD34 Ϫ AT-MSCs [45] . Several studies have compared BM-MSCs and AT-MSCs, but mostly small groups of donors and different patient groups and age groups were investigated. Those studies reported that ATMSCs and BM-MSCs both exhibit the capacity to inhibit PBMC proliferation but indicated no differences between the MSC populations [30, 32, 34 -36] . We also showed that both populations are able to inhibit PBMC proliferation, but with a different doseresponse curve. Others used MSC concentrations at the plateau phase of the dose-response curve and MSCs from different patient groups and age. Therefore they did not find differences in potency between AT-MSCs and BM-MSCs. We showed that differences were found only at concentrations in the linear phase of the dose-response curve.
The more potent suppression of PBMC proliferation by ATMSCs than by BM-MSCs was also reflected in the cytokine concentrations measured in the coculture supernatants of the PBMC-MSC cocultures. Our data suggest that both BM-MSCs and AT-MSCs induce a shift from a Th1 toward a Th2 response, since concentrations of the proinflammatory cytokines IL-12, TNF-␣, and IFN-␥ were significantly reduced in culture supernatants of PBMCs cultured in the presence of either type of MSCs. This effect was stronger in the presence of AT-MSCs than in the presence of BM-MSCs, and for IFN-␥ this difference between ATMSCs and BM-MSCs became statistically significant.
IFN-␥ has also been implicated in the initiation of the immunosuppressive function of MSCs. Activation of MSCs by IFN-␥ is involved in the inhibitory effect of MSCs on T-cell proliferation through induction of expression of IDO, an enzyme that catabolizes tryptophan [13] . The level of induced IDO expression differs between MSC populations and has been correlated to their immunosuppressive potential [46] . We found that, in response to IFN-␥, IDO expression is induced to higher levels in AT-MSCs than in BM-MSCs. The more potent inhibitory effect of AT-MSCs on PBMC proliferation can be explained by this stronger response to IFN-␥; that is, the IFN-␥ that is produced by the activated PBMCs causes a stronger or more adequate response of the AT-MSCs resulting in stronger inhibition of the PBMC proliferation, finally resulting in lower concentrations of IFN-␥ and other proinflammatory cytokines. We have shown in vitro that MSCs inhibit monocyte differentiation toward iDCs and rather skew monocytes toward a tolerogenic cell type, with increased secretion of the immunomodulatory cytokine IL-10 [47] . In our monocyte-MSC cocultures, the secretion of the immunomodulatory cytokine IL-10 was more pronounced in the presence of AT-MSCs than in the presence of BM-MSCs. This indicates that the monocytes have become more tolerogenic in the presence of ATMSCs. Since activated monocytes have been shown to increase their IL-10 expression upon IL-10 exposure, creating a positive feedback loop [48] , this difference in effect of AT-versus BMMSCs might even be further enhanced.
Compared with BM-MSCs, AT-MSCs constitutively secrete higher levels of multiple cytokines that have been implicated in MSC-mediated immunomodulation, such as IL-6 and TGF-␤1 [5, 11, 49, 50] . We have shown that IL-6 is a key factor for the MSCinduced inhibition of monocyte differentiation toward iDCs and the induction of IL-10 secretion by monocytes [47] . The higher IL-6 secretion by AT-MSCs can therefore explain the more pronounced inhibition of iDC generation and the increased IL-10 protein concentrations that were observed in the monocyte cultures in the presence of AT-MSCs. TGF-␤1 has been implicated in the generation of regulatory T cells by MSCs [11, 14] . Therefore, we hypothesize that the observed higher TGF-␤1 production by AT-MSCs may also be associated with an increased ability to induce regulatory T cells.
The overall explanation for the observed functional superiority of AT-MSCs may be their higher metabolic activity, resulting in production of higher levels of cytokines that are involved in the immunosuppressive mechanisms of MSCs. It is therefore conceivable that this also holds true for other factors that are involved in immunomodulation by MSCs, such as PGE2 [30, 51] , galectin-1 [52, 53] , and HLA-G5 [54] .
CONCLUSION
Our data show that BM-MSCs and AT-MSCs share a similar immunophenotype and capacity for in vitro multilineage differentiation. Also, functionally, BM-MSCs and AT-MSCs show similar immunomodulatory effects, but with a different dose-response curve, in favor of AT-MSCs. We show that the differences in immunomodulatory properties between BM-MSCs and AT-MSCs are primarily due to the quantitative aspects of the suppression, which are likely related to their respective metabolic activity. These data support the notion that AT-MSCs could be a promising alternative to BM-MSCs for future clinical immunomodulatory applications.
